Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

2012 are primarily due to a $25.0 million milestone achieved upon the acceptance of the naloxegol MAA filing in Europe as well as increased product sales.  In addition, revenue in the first nine months of 2013 increased as compared to the same period in 2012 due to a $10.0 million milestone achieved upon the initiation of Phase 3 studies for Amikacin Inhale in April 2013.

Total operating costs and expenses in the third quarter of 2013 were $67.4 million as compared to $51.3 million in the third quarter of 2012.  Year-to-date total operating costs and expenses in 2013 were $202.0 million as compared to $157.9 million for the same period in 2012.  Total operating costs and expenses increased primarily as a result of increased clinical development expenses.

Research and development expenses in the third quarter of 2013 were $43.9 million as compared to $34.0 million in the third quarter of 2012.  Year-to-date R&D expense for 2013 was $141.8 million as compared to $102.3 million for the same period in 2012.  R&D expense was higher in the third quarter and the first nine months of 2013 as compared to the same periods in 2012 reflecting the costs of the Phase 3 study of etirinotecan pegol (NKTR-102) in metastatic breast cancer, the Phase 2 study of NKTR-181, preparation for the Phase 3 study of NKTR-181, the Phase 1 study of NKTR-192, and the production of devices for the Phase 3 study of Amikacin Inhale.

General and administrative expense was $10.6 million in the third quarter of 2013 as compared to $10.1 million in the third quarter of 2012.  G&A expense in the first nine months of 2013 was $30.7 million as compared to $30.8 million for the same period in 2012.

Non-cash interest expense incurred in connection with the 2012 royalty monetization was $5.6 million and $16.6 million in the third quarter and first nine months of 2013, respectively, as compared to $5.5 million and $12.6 million in the
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, ... announced a strategic collaboration to discover and develop ... The new collaboration builds on a broad existing ... strategic approach in these therapeutic areas using novel ... extend use of its antisense technology to diseases ...
(Date:7/31/2015)... 2015  In today,s ever-changing marketplace, call centers must ... increasingly connected, and increasingly impatient with slow service. The ... channels and tools is driving call centers to explore ... According to research by benchmarking firm, Best Practices, ... in a call center study realize the impact of ...
(Date:7/31/2015)... 2015 RnRMarketResearch.com adds Syringes ... report that provides an overview of syringes and ... from in-house databases, secondary and primary research. ... products pipeline spread across 124 pages, talking about ... and 5 figures is now available at ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... CHICAGO, Nov. 10 Advanced Life Sciences Holdings, ... engaged in the discovery, development and commercialization of novel ... respiratory diseases, today announced its financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO ) , The net loss ...
... NEW YORK, Nov. 10 Reportlinker.com announces ... available in its catalogue. , The ... Market Outlook , http://www.reportlinker.com/p0158356/The-Global-Drug-Delivery-Market-Research-Trends-and-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... drug delivery industry has in recent years ...
Cached Medicine Technology:Advanced Life Sciences Announces Third Quarter 2009 Financial Results 2Advanced Life Sciences Announces Third Quarter 2009 Financial Results 3Advanced Life Sciences Announces Third Quarter 2009 Financial Results 4Advanced Life Sciences Announces Third Quarter 2009 Financial Results 5Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6Advanced Life Sciences Announces Third Quarter 2009 Financial Results 7Advanced Life Sciences Announces Third Quarter 2009 Financial Results 8Advanced Life Sciences Announces Third Quarter 2009 Financial Results 9Advanced Life Sciences Announces Third Quarter 2009 Financial Results 10Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 2Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 3Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 4Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 5Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 6Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 7Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 8Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 9Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 10Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 11
(Date:8/3/2015)... Scottsdale, AZ (PRWEB) , ... ... ... Services, Inc. (EMSI), a leading provider of medical information, risk management and ... the company’s evolution and direction toward focused, expert information solutions that improve ...
(Date:8/3/2015)... ... ... Did you know that there are thousands of Seniors or Elderly ... options which A-1 Home Care Agency specialize in? In fact, diversity, multi-cultural, financing options, ... Care Agency is known for. , With all the Los Angeles ...
(Date:8/2/2015)... ... 03, 2015 , ... Career Step, an online institution offering ... for Healthcare Documentation Integrity’s (AHDI) conference being held in Alexandria, Virginia, on Friday ... AHDI conference provides us to interact with those in the healthcare documentation industry,” ...
(Date:8/2/2015)... ... , ... For many “would be” entrepreneurs, starting a new business can prove to be ... start a business.” Neither needs be a major obstacle. , The U.S. has always ... business and be successful. The risks of starting a business can be high but the ...
(Date:8/2/2015)... ... 2015 , ... Molecular biologists in New South Wales say a protein linked ... just posted an article on the new research. Click here to read it ... expression in tissue samples from 42 patients with peritoneal mesothelioma and found a direct ...
Breaking Medicine News(10 mins):Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2
... of fathers in the United Kingdom appear to experience an ... of age, with the highest rates in the first year ... will appear in the November print issue of Archives ... journals. "Depression in parents is associated with adverse behavioral, ...
... HealthDay Reporter , FRIDAY, Sept. 3 (HealthDay News) -- ... lead to diabetes, a new study finds. Fish oil ... one of the most popular dietary supplements in the United ... beneficial, exactly how they work hasn,t been well understood, said ...
... Amanda Gardner HealthDay Reporter , FRIDAY, Sept. 3 ... in flophouses, theaters and high-end offices, bedbugs are popping up ... more places than just your bed. According ... 95 percent of U.S. pest management companies surveyed said they ...
... have found that people with Parkinson,s disease can perform ... have significant difficulty switching from easy to hard tasks. ... of the illness that affect the brain,s ability to ... Parkinson,s disease as being a disorder of motor function," ...
... large international study aimed at improving the care ... by physicians, physical therapists, and researchers at the ... "Berch" Griggs, M.D., is heading the study of ... form of the disease that affects children. The ...
... with advanced disease in palliative care settings receive oxygen therapy ... study from Duke University Medical Center says roughly half of ... do benefit, it doesn,t make a bit of difference whether ... both offer equal benefit. "Offering oxygen when patients ...
Cached Medicine News:Health News:Parents at highest risk for depression in the first year after child's birth 2Health News: Mouse Study May Help Explain Fish Oil's Benefits 2Health News: Mouse Study May Help Explain Fish Oil's Benefits 3Health News:Bedbug Nation: Critters Make a Comeback 2Health News:Bedbug Nation: Critters Make a Comeback 3Health News:Bedbug Nation: Critters Make a Comeback 4Health News:Rochester leads international effort to improve muscular dystrophy treatment 2Health News:Rochester leads international effort to improve muscular dystrophy treatment 3Health News:Rochester leads international effort to improve muscular dystrophy treatment 4Health News:Study challenges value of oxygen therapy in end-of-life care 2Health News:Study challenges value of oxygen therapy in end-of-life care 3
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: